Results: 2

1.
Figure 1

Figure 1. From: FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.

Time to progression (A) and overall survival (B) from the beginning of FOLFIRI for the 63 patients. TTP: Time to progression; OS: Overall survival.

Cindy Neuzillet, et al. World J Gastroenterol. 2012 September 7;18(33):4533-4541.
2.
Figure 2

Figure 2. From: FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.

Subgroup analysis according to the World Health Organization performance status. A: Time to progression (TTP) according to World Health Organization (WHO) performance status (PS). B: Overall survival (OS) according to WHO PS.

Cindy Neuzillet, et al. World J Gastroenterol. 2012 September 7;18(33):4533-4541.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk